Peptifact

SLU-PP-332 Side Effects: No Human Has Been Studied, and the Mouse Papers Were Not Designed to Look

SLU-PP-332 has no human trial, no registry entry and no FDA adverse-event report. Its entire safety record is what five short mouse studies happened to notice — including one its own developers cut short because the mice tolerated the injections poorly. The census, what was measured, and what nobody has checked.

Robert F · Edited by Caroline S · Published 2026-09-30 · Updated 2026-10-10

Illustration: A clean, partially disassembled laboratory pipette and an empty glass vial on a cool grey lab bench.
Illustration

SLU-PP-332 is marketed as an "exercise mimetic": a compound that switches on some of the genes a bout of aerobic exercise switches on. It is sold as tablets, capsules and injection vials, often next to research peptides, although it is a small synthetic molecule, not a peptide. The dosing record — every figure in the literature is a mouse dose by injection — is on our SLU-PP-332 dosage page. This page asks the other question: what is known about harm.

The short answer is that no human has ever been studied, and the animal studies were not designed to find harm. What follows is the full census, so the absence can be checked rather than taken on trust.

The record, counted

Searched on 30 September 2026, and re-run on 10 October 2026 with the same result in all three places:

Where a finding would be Query Result
ClinicalTrials.gov (v2 API) "SLU-PP-332" 0 studies
openFDA adverse-event database (FAERS) product name "SLU-PP-332" 0 reports
PubMed "SLU-PP-332" 10 records

The ten PubMed records sort into five studies in live mice (2023–2026, one of them mainly about the successor molecule SLU-PP-915), two anti-doping metabolism studies in human liver fractions (2026), one study in cultured human muscle cells (2025), one medicinal-chemistry paper (2026), and one Spanish-language systematic review in Revista Médica de Chile (2026). There is no human dosing study of any kind.

What the mouse studies noticed

The in vivo work comes from the laboratory that designed the compound and its collaborators. It was built to measure metabolism, exercise capacity, kidney ageing and heart failure, so safety observations appear only in passing:

  • Poor tolerance of the injections. In the 2024 metabolic-syndrome study, male mice received 50 mg/kg by intraperitoneal injection twice daily. The methods state that the arm in genetically obese ob/ob mice was "shortened to 12 days due to reduced tolerance of twice per day intraperitoneal administration." The paper does not describe what the reduced tolerance looked like.
  • Weight loss without eating less. Diet-induced obese mice weighed about 12% less than vehicle-treated mice after 28 days; vehicle mice gained about 5 g of fat against under 0.5 g on the drug, with no significant difference in food intake or lean mass. The authors frame this as the intended effect. It is also an unexplained increase in energy expenditure, and nobody measured body temperature or heart rate while it happened.
  • Blood tests. The same paper reports "only relatively minor changes in plasma cholesterol and liver enzyme levels" in lean mice, and falls in total cholesterol, HDL and triglycerides in obese mice. No kidney or blood-count panel is reported.
  • Heart. In the 2024 Circulation heart-failure study, mice with surgically induced pressure overload were given 25 mg/kg twice daily; SLU-PP-332 improved ejection fraction and survival and did not change heart wall thickening. The paper states, for the related molecule SLU-PP-915, that it saw no "overt toxicity" over six weeks; it makes no equivalent statement for SLU-PP-332. It also reports that activating these receptors switched off genes for cell division and development in heart muscle cells.

Every one of these studies injected the compound into the abdominal cavity, for no longer than about eight weeks. The two papers we read in full used a vehicle of DMSO and Cremophor in saline — a solvent mix that has effects of its own — and the metabolic study states that its animals were male; neither reports work in females.

Each study, what it gave and how long it watched

Study (year, PMID) Animals Dose and route Longest exposure Safety reporting
Discovery paper, ACS Chem Biol (2023, 36988910) Mice Injection into the abdomen Short exercise-capacity experiments Endurance and muscle-fibre outcomes only
Ageing kidney, Am J Pathol (2023, 37717940) 21-month-old mice Injection 8 weeks Kidney markers improved (albuminuria, podocyte loss); no general toxicology
Metabolic syndrome, J Pharmacol Exp Ther (2024, 37739806) Male mice, diet-induced obese and ob/ob 50 mg/kg twice daily, abdominal injection 28 days; ob/ob arm cut to 12 days for poor tolerance Cholesterol and liver enzymes "relatively minor changes"
Heart failure, Circulation (2024, 37961903) Mice after pressure-overload surgery 25 mg/kg twice daily Weeks (the six-week toxicity remark is about SLU-PP-915) "No overt toxicity" stated for SLU-PP-915, not for SLU-PP-332
Successor molecule, J Pharmacol Exp Ther (2026, 41421047) Mice Abdominal injection, compared with oral SLU-PP-915 Short exercise experiments None for SLU-PP-332; states it "lacks oral bioavailability"

The one study involving human tissue (Bonanni et al., Frontiers in Physiology, 2025, PMID 40692696) took muscle biopsies from 20 women having hip replacements and treated the cells from the 10 inactive women in a dish. SLU-PP-332 lowered markers of oxidative stress and cell ageing and helped the cells form muscle fibres. That is a laboratory cell result; no person received the compound.

Who did the research

Every study in live animals came from the group that designed SLU-PP-332 or its collaborators. The 2023 discovery paper declares that three of its authors, including the senior author, are stockholders in Myonid Therapeutics, "which focuses on ERR based therapeutics." The 2026 paper on the successor molecule states that SLU-PP-915 is Saint Louis University intellectual property with the senior author as inventor, and that he also holds stock in Pelagos Pharmaceuticals, also developing ERR agonists. The 2023 kidney study and the 2025 human-cell study declare no conflicts. None of this makes the results wrong. It does mean that no group without a stake in the compound class has yet tried to reproduce the animal findings, and that the developers have said they moved on to a different molecule for oral use.

What nobody has looked at

No published study of SLU-PP-332 reports any of the following:

  • A toxicology programme of the kind a drug needs before first use in people: single- and repeat-dose toxicity in two species, genotoxicity, safety pharmacology (heart rhythm, blood pressure, breathing, nervous system), reproductive or developmental studies.
  • Any study designed to compare effects in female animals.
  • Any data by mouth. The developers wrote in January 2026 that SLU-PP-332 "lacks oral bioavailability", and moved to a different molecule for oral work. Tablets and capsules are what is sold.
  • Heart rate or body temperature during the rise in energy expenditure.
  • Interactions with other drugs, although the anti-doping laboratories show it is extensively metabolised by the liver — into 22 metabolites in the UCLA study and 9 in the Cologne study.

Where the human side-effect lists come from

Vendor and forum pages circulate lists of human side effects. None of them traces to any study of SLU-PP-332 in people, because there is none. They are user reports from an unverified product of unknown content, and this page records them as a category of claim, not as evidence. A reader cannot tell from such a report whether the tablet contained SLU-PP-332, how much, or what else.

What regulators and sports bodies have said

FDA's adverse-event database holds no report naming it. The anti-doping world has moved faster than the medical one: the UCLA Olympic Analytical Laboratory states that the World Anti-Doping Agency prohibits exercise mimetics and metabolic modulators, and both it and the Cologne laboratory published detection methods in 2026. The 2026 systematic review in Revista Médica de Chile concludes that "clinical trials are needed to confirm their efficacy and safety in humans."

Reading this record

"No reported side effects" and "no known side effects" are the wrong summaries here. The accurate one is that the compound has never been given to a person under observation, and that the animal studies were short, single-sex, injected and aimed elsewhere. Anyone who has taken it and has symptoms, or is weighing it, should take the question to a doctor and say what the product was and how it was sourced.

The wider pattern — why low report counts for research compounds mean little — is on our peptide side-effects overview. A close cousin in the metabolic research market with a similarly thin record is covered on our 5-amino-1MQ dosage page, and the question of why almost nothing sold as a tablet in this market has had its absorption measured is on our oral peptides page. What the compound is and how it acts is summarised in Peptide Lexicon's SLU-PP-332 entry. Its safety census, which turned up a 3.5% oral absorption figure in mice, is on our 5-amino-1MQ side-effects page.

Sources and dates

  • ClinicalTrials.gov v2 API, term "SLU-PP-332": 0 studies, 2026-09-30. openFDA drug adverse-event endpoint, medicinal product "SLU-PP-332": no matches, 2026-09-30 (dataset updated 2026-07-30).
  • PubMed via NCBI E-utilities, "SLU-PP-332": 10 records, abstracts read 2026-09-30.
  • Billon C et al. A synthetic ERR agonist alleviates metabolic syndrome. J Pharmacol Exp Ther 2024;388(2):232-240 (PMID 37739806; full text PMC10801787, methods and results read).
  • Xu W et al. Novel pan-ERR agonists ameliorate heart failure. Circulation 2024;149(3):227-250 (PMID 37961903; full text PMC10842599, methods and results read).
  • Wang XX et al. Am J Pathol 2023;193(12):1969-1987 (PMID 37717940). Billon C et al. J Pharmacol Exp Ther 2026;393(1):103787 (PMID 41421047).
  • Avliyakulov NK et al. Drug Test Anal 2026;18(3):439-450 (PMID 41688415). Möller T et al. Rapid Commun Mass Spectrom 2026;40(8):e70039 (PMID 41588687).
  • Billon C et al. Synthetic ERRα/β/γ agonist induces an ERRα-dependent acute aerobic exercise response. ACS Chem Biol 2023;18(4):756-771 (PMID 36988910; conflict-of-interest statement read).
  • Bonanni R et al. Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity. Front Physiol 2025;16:1616693 (PMID 40692696).
  • Census re-run 2026-10-10: ClinicalTrials.gov 0, openFDA no matches, PubMed 10 records (unchanged).
  • de Souza-Lima J et al. Rev Med Chil 2026;154(2):237-245 (PMID 42024694).

Corrections go to the contact page.

Frequently asked questions

What are the side effects of SLU-PP-332?

No one knows for people, because no human has been studied. There is no registered trial, no published case report and no FDA adverse-event report naming it. The only in vivo data are four studies in male mice given injections into the abdomen. In one, genetically obese mice tolerated twice-daily injections poorly enough that the study was shortened to 12 days. Lists of human side effects on vendor and forum pages do not trace to any study.

Is SLU-PP-332 safe?

The record cannot answer that. Absence of reported harm here is absence of looking: the mouse studies were built to measure metabolism and exercise capacity, not safety, and none ran a standard toxicology programme. A 2026 systematic review concluded that clinical trials are needed to confirm its efficacy and safety in humans.

Does SLU-PP-332 cause weight loss or muscle loss?

In diet-induced obese male mice given 50 mg/kg twice daily by injection, body weight fell about 12% relative to vehicle over 28 days, driven by less fat gain; lean mass and food intake did not differ significantly. Whether anything similar happens in people, at any dose or by mouth, has not been tested.

Is SLU-PP-332 banned in sport?

Anti-doping laboratories treat it as a prohibited exercise mimetic and metabolic modulator. Two of them published human-liver metabolism studies in 2026 specifically so that its use can be detected in urine tests. Athletes subject to testing should check the current World Anti-Doping Agency list with their federation.

Is SLU-PP-332 a peptide?

No. It is a small synthetic molecule of molecular weight 290, sold alongside research peptides. That matters for side effects because none of the peptide-specific concerns, such as injection-site reactions to a protein or antibody formation, carry the same meaning, while small-molecule concerns such as liver metabolism and off-target effects have not been studied either.